Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Terconazol in vaginal candidiasis. Comparative study].

V Llaca Rodríguez1, H Carrión Tizcareño, P Arguelles Domenzain

  • 1Centro Médico Naval, División de Ginecología y Obstetricia, México,D.F.

Ginecologia Y Obstetricia De Mexico
|November 1, 1990
PubMed
Summary

Terconazole effectively treats vaginal candidiasis, achieving high mycological cure rates. However, partner treatment is crucial to prevent recurring infections, as demonstrated by higher relapse rates when partners were untreated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comparative evaluation of bone mineral density in Mexican women using x-ray bone densitometry and ultrasound].

Ginecologia y obstetricia de Mexico·2000
Same author

[Homage to Dr. Alfredo López de Nava].

Ginecologia y obstetricia de Mexico·1992
Same author

[Terconazole in vaginal candidiasis. A comparative study].

Ginecologia y obstetricia de Mexico·1990
Same author

[Premature labor as a factor in high fetal risk pregnancy].

Ginecologia y obstetricia de Mexico·1979
Same author

[Epidemiological considerations on vaginal candidiasis].

Ginecologia y obstetricia de Mexico·1979
Same author

[Correlation of placentography with estrioluria].

Ginecologia y obstetricia de Mexico·1979

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Vaginal candidiasis is a common fungal infection.
  • Recurrence is a significant challenge in managing vaginal candidiasis.
  • Antifungal resistance and treatment adherence impact therapeutic outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of terconazole for vaginal candidiasis.
  • To compare terconazole with clotrimazole in treating vaginal candidiasis.
  • To assess the impact of partner treatment on recurrence rates.

Main Methods:

  • A blind study involving 60 patients with vaginal candidiasis.
  • Terconazole administered as vaginal ovules (VO) in two dosage regimens (240 mg single dose, 80 mg daily for 3 days).

Related Experiment Videos

  • Comparison with clotrimazole (200 mg daily for 3 days); partner treatment varied between groups.

    • Main Results:

    • High initial mycological cure rates at 10 days: 90% (terconazole 240 mg), 95% (terconazole 80 mg/3 days), and 95% (clotrimazole).
    • Recurrence rates at 28 days were 50% (terconazole 240 mg), 40% (terconazole 80 mg/3 days), and 15% (clotrimazole).
    • Higher recurrence in terconazole groups was linked to untreated partners.

    Conclusions:

    • Terconazole demonstrates significant clinical and mycological efficacy in treating vaginal candidiasis.
    • Partner treatment is essential to prevent reinfection and reduce recurrence rates.
    • Further research should explore optimal partner management strategies for recurrent vaginal candidiasis.